## VRTX: Vertex Pharmaceuticals Incorpor - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 0.58 indicates fundamental undervaluation. Quality metrics strong (ROE 22%, ROA 12%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($418.88)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 1, Bearish: 0)

**1. State Street Corp Has $5.24 Billion Holdings in Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251209T131408 | Somewhat-Bullish | Relevance: 100%
-  State Street Corp trimmed its stake in Vertex Pharmaceuticals (VRTX) by 0.1%, holding 11,775,227 shares valued at $5.24 billion. The pharmaceutical company exceeded quarterly expectations with an EPS of $4.80 and revenue of $3.08 billion, despite some insider selling and a slight dip in stock price. Institutional investors own 90.96% of the company, and analysts have a "Moderate Buy" rating with an average target price of $495.53.

**2. First Trust Advisors LP Purchases 143,084 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251206T093359 | Neutral | Relevance: 100%
-  First Trust Advisors LP increased its stake in Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) by 98.8% in Q2, purchasing an additional 143,084 shares and bringing its total holdings to 287,892 shares valued at $128.17 million. This comes as institutional ownership of the company reaches 90.96%, with several other funds also adjusting their positions. Insider transactions show recent sales by EVP Charles F. Wagner, Jr. and Chairman Jeffrey M. Leiden, while analysts have a "Moderate Buy" rating for the stock with a consensus target price of $498.25.

**3. Axa S.A. Buys 10,477 Shares of Vertex Pharmaceuticals Incorporated $VRTX**
- Source: MarketBeat | 20251209T083101 | Somewhat-Bullish | Relevance: 99%
-  Axa S.A. increased its stake in Vertex Pharmaceuticals (NASDAQ:VRTX) by 6.5% during the second quarter, acquiring an additional 10,477 shares, now holding 171,270 shares valued at $76.25 million. The pharmaceutical company exceeded Q3 earning expectations with an EPS of $4.80 and revenue of $3.08 billion, prompting analysts to maintain a "Moderate Buy" rating with a consensus price target of $495.53. Despite institutional buying, company insiders have been net sellers, offloading over 151,000 shares worth approximately $67.3 million in the past three months.

**4. Vertex Presents New Data on CASGEVYÂ®, Including First-Ever Data in Children Ages 5-11 Years, at the American Society of Hematology Annual Meeting and Announces Plan for Global Regulatory Submissions**
- Source: Business Wire | 20251206T120833 | Bullish | Relevance: 99%
- Vertex Pharmaceuticals announced new clinical data for CASGEVY (exagamglogene autotemcel) in patients aged 5 years and older with severe sickle cell disease (SCD) or transfusion-dependent beta thalassemia (TDT), including the first-ever data from children aged 5-11. The results from pivotal studies in younger patients proved consistent with the established positive safety and efficacy profile observed in patients 12 years and older. Vertex plans to initiate global regulatory submissions for CASGEVY in eligible children aged 5-11 years in the first half of 2026.

**5. Vertex Pharmaceuticals (NASDAQ:VRTX) Chairman Jeffrey Leiden Sells 63,781 Shares**
- Source: MarketBeat | 20251206T230836 | Neutral | Relevance: 99%
- Jeffrey Leiden, Chairman of Vertex Pharmaceuticals (NASDAQ:VRTX), sold 63,781 shares of the company's stock for approximately $28.65 million on December 3rd, reducing his ownership by 72.64%. The sale occurred after the company reported strong quarterly earnings, beating analyst estimates with an EPS of $4.80 and revenue of $3.08 billion, an 11% year-over-year increase. Analysts currently rate VRTX as a "Moderate Buy" with an average price target of $498.25.

### Analyst Activity

**Target Signal:** BULLISH (Raises: 2, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Morgan Stanley | $564 | $516 | +9% |
| 2025-12-03 | Morgan Stanley | $516 | $438 | +18% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Morgan Stanley | main | Overweight |
| 2025-12-03 | Morgan Stanley | up | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 3 ($3.52M) |
| Sells | 10 ($11.24M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 52.5% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Capital World Invest: 10.2% (-9.8%)
- Vanguard Group Inc: 9.5% (+1.0%)
- Blackrock Inc.: 8.8% (+1.7%)
- Capital Research Glo: 6.5% (+2.8%)
- JPMORGAN CHASE & CO: 5.1% (+119.3%)

### Key Risks

1. Heavy insider selling: $11M sold (10 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 0.58 indicates undervaluation relative to growth. Forward P/E 21.9x stretched relative to 9% growth. Quality metrics strong (ROE 22%, ROA 12%, margin 31%). Balance sheet: strong liquidity (2.4x), low leverage (D/E 0.44), $1.1B free cash flow. Analyst sentiment positive (2 raises, avg +14%). Insider selling cluster ($11.2M in 90 days), potential headwind. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $113.3B |
| Beta | 0.32 |
| 52W Range | $362.50 - $519.68 |
| Short Interest | 1.8% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 0.58 |
| Forward P/E | 21.9 |
| Current P/E | 24.0 |
| YoY Growth | 9.5% |
| EPS Direction | STABLE |

### Technicals

MRS_20 stable at -0.3% (minimal 5-day change). Below STRENGTH zone by 4.3pp (needs >4.0% for momentum thesis). Outperforming sector by 3.0pp, stock-specific strength. Below SMA200 (1.00x), long-term trend not supportive. MACD histogram positive (1.72), confirming momentum. RSI neutral at 56.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -0.34% (CS: 55) | Neutral |
| RSI_14 | 55.6 | Neutral |
| MACD Histogram | 1.72 | Bullish |
| vs SMA20 | 1.017x | Above |
| vs SMA50 | 1.047x | Above |
| vs SMA200 | 0.999x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $442.04
- **Stop Loss:** $418.88 (5.2% risk)
- **Target:** $488.36 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 21
- **Position Value:** $9,282.84
- **Portfolio %:** 9.28%
- **Risk Dollars:** $500.00
- **Risk Per Trade:** 0.50%
- **Modifiers:** L1 100% | L2 50% | Combined 0.50x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | AVOID (Zone C) | 0.50x |

### Earnings

**Next:** 2026-02-09 (Est: $5.17)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $4.58 | $4.80 | +4.9% |
| 2025Q2 | $4.25 | $4.52 | +6.3% |
| 2025Q1 | $4.29 | $4.06 | -5.4% |
| 2024Q4 | $4.02 | $3.98 | -1.0% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*